The relationship between Runt-related transcription factor 3 (RUNX3) gene inactivation and various solid tumors has been reported; however, little information is available about RUNX3 in thyroid cancers. Methods: We evaluated the DNA methylation of RUNX3 in 13 papillary thyroid cancer tissues and four thyroid cancer cell lines. Additionally, using reverse transcriptase-polymerase chain reaction, we analyzed RUNX3 gene expression in several thyroid cancer cell lines after treating with the demethylating agent 5-aza-2'-deoxycytidine (DAC). Results: RUNX3 was hypermethylated in many thyroid cancer cell lines and in 10 of the 12 papillary thyroid cancer tissues. Treatment with DAC increased the expression of RUNX3 in some thyroid cancer cell lines.
INTRODUCTION
Runt-related transcription factor 3 (RUNX3) has strong tumor suppressor activity, which is involved in the regulation of epithelial proliferation and apoptosis [1, 2] . Inactivation of the RUNX3 gene has been reported in many human solid tumors. The RUNX family consists of three members: RUNX1 (PEBP2Ab/CBFA2/ AML1), RUNX2 (PEBP2Aa/CBFA1/AML3), and RUNX3 (PEBP2Ac/CBFA3/AML2). RUNX1, located on chromosome 21q22.3, is related to hematopoiesis, and its mutation has been reported in human acute leukemia and myelodysplastic syndrome. RUNX2, located on chromosome 6q21, has been linked to bone formation. RUNX3, located on chromosome 1p36, plays an important role in the development of cancer [3] [4] [5] .
RUNX3 gene inactivation has been reported in gastric cancer, colorectal cancer, lung cancer, pancreatic ca ncer, bladder cancer, breast cancer, and hepatocellular carcinoma [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . However, little information is available about the role of RUNX3 in thyroid cancers. To determine whether methylation of RUNX3 is related to carcinogenesis of the thyroid, we evaluated DNA methylation of RUNX3 in 13 papillary thyroid cancer tissues and four thyroid cancer cell lines. RUNX3 gene expression in some thyroid cancer cell lines after 5-aza-2'-deoxycytidine (DAC) treatment was also analyzed using reverse transcriptase-polymerase chain reaction (RT-PCR).
METHODS

Tissues and cell lines
Human thyroid tissues collected during surgery were immediately frozen in liquid nitrogen. We examined 13 tumor tissue samples (12 papillary thyroid carcinomas 
Combined bisulfite restriction analysis (COBRA)
The sodium bisulfite-modified DNA was amplified 
RESULTS
DNA methylation of RUNX3 in cell lines and tissues
COBRA was performed to analyze the methylation status of the RUNX3 CpG islands in human thyroid cancer cell lines and thyroid cancer tissues. Almost all thyroid cancer cell lines showed increased methylation of RUNX3 (Fig. 1) . Among the thyroid cancer cell lines studied, WRO and TPC1 had extremely hypermethylated RUNX3, at over 90% (Table 1) . RUNX3 was hypermethylated in 10 of the 12 papillary thyroid cancer tissues and was not methylated in five normal thyroid tissues. One Hurthle cell adenoma tissue was not hypermethylated (Fig. 2) .
DAC and TSA treatment in cell lines
Two human thyroid cancer cell lines (WRO and TPC1) were treated with the demethylating agent DAC and histone-deacetylating agent TSA in an attempt to reactivate RUNX3. DAC treatment resulted in a dose dependent increase in expression of RUNX3 (Fig. 3) .
DISCUSSION
Recently, many reports have described the association of RUNX3 gene inactivation with different solid cancers. However, little information is available on the relationship between RUNX3 and thyroid cancer. In this study, we analyzed the methylation status of RUNX3 in thyroid cancer and showed that RUNX3 was hypermethylated in various thyroid cancer cell lines and PTC tissues.
Promoter hypermethylation is considered to be a main mechanism for gene inactivation. Hypermethylation of CpG islands located in the promoter regions of tumor suppressor genes is associated with cell pathway disruption and transcriptional inactivation. CpG island hypermethylation has been reported in stomach cancer, hepatocellular carcinoma, lung cancer, breast cancer, and pancreatic cancer. RUNX3 is silenced by hypermethylation of CpG islands in the promoter region [16, 17] .
The exact tumor suppressive action of RUNX3 is not clear. RUNX3 is an integral component of TGF-β that induces cell signal pathways. The gastric epithelium of RUNX3 knock-out mice show reduced apoptosis and decreased sensitivity of the RUNX3 gene-associated TGF-β signaling pathway [18] . TGF-β regulates the G1 phase of the cell cycle, and reduced TGF-β sensitivity induces growth arrest associated with apoptosis [19, 20] .
In this study, RUNX3 hypermethylation was present in papillary thyroid cancer cell lines, follicular thyroid cancer cell lines and anaplastic thyroid cancer cell lines. The DNA from blood of normal healthy person (normal) was used as a negative control. The SssI methylase treated-blood DNA (SssI) was used as a positive control. 
